Our understanding of COVID-19 has evolved greatly since its first appearance in the U.S. in early 2020. Though our knowledge remains incomplete, we’ve learned a lot about the pathophysiology of the virus—especially its unique effects on the heart.
As use of cannabis products increases and evidence of possible cardiovascular harm mounts, it’s time for cardiologists to start having conversations with their patients.
Following data supporting their use for heart failure and type 2 diabetes, will sodium-glucose cotransporter 2 inhibitors find a spot in the heart failure armamentarium?
As many as 700 hearts from donors with hepatitis C are discarded each year in the U.S. New research suggests at least some of these organs may be suitable for transplant.
Even the best analytics won’t replace human interaction; protect your time with patients and colleagues. Focus on the patient-centered metrics, and try to be patient. It takes time to turn a mess into a masterpiece.
To get the operational perspective, CVB hosted a roundtable discussion with service line leaders about the opportunities and challenges they encounter around data.
With use of cardiac implantable electronic devices on the rise, experts stress device selection, prophylactic antibiotics, pre-procedural protocols and post-implementation vigilance.
New cholesterol guidelines from the American Heart Association and the American College of Cardiology recommend adding ezetimibe and/or PCSK9 inhibitors to statin therapy for select high-risk patients, and also propose using coronary artery calcium (CAC) scoring as “a tiebreaker” to guide statin decisions for those at intermediate risk of atherosclerotic cardiovascular disease.
